RudaCure (CEO Yongho Kim), a 生物科技公司 specializing in novel 药物开发, announced on the 3rd that it has been selected for the 2025 Agri-Food Venture Development Support Program organized by the 农林畜产食品部, and will commence full-scale development of a 兽用 gene-based 疼痛治疗药.
The 'Agri-Food Venture Development Support Program' is a government support program designed to discover and nurture promising ventures and 初创企业s that will drive high value-added growth in the agri-food industry. Each year, it selects promising projects through rigorous evaluation with the aim of creating future food sources and industrial competitiveness in the agricultural and livestock sectors based on innovative technology.
This project aims to develop a 基因治疗 that induces 非麻醉性镇痛药 effects for application in 慢性疼痛 management of 伴侣动物 and high-value animals such as racehorses. RudaCure has secured innovative technology that achieves long-term 疼痛缓解 with a single administration using its proprietary 离子通道-targeted peptide delivered via AAV (Adeno-Associated Virus) vectors.
According to RudaCure, preliminary test results show that the treatment provides continuous 镇痛效果 for more than 3 months with just a single administration. The global 兽用 疼痛治疗市场 is growing rapidly at approximately $2 billion per year, and there is rising demand for innovative treatments that move beyond existing NSAIDs and opioid-based drugs.
CEO Kim stated, "Being selected for this support program is recognition of the innovative technology we have accumulated in the 兽用 基因治疗 field. Through this project, we will accelerate the development of 兽用 疼痛治疗药s and advance into the 全球市场."
